(ACB) Aurora Cannabis - Ratings and Ratios
Cannabis, Cannabis-Derivative Products, Vegetables, Floral Plants
ACB EPS (Earnings per Share)
ACB Revenue
Description: ACB Aurora Cannabis
Aurora Cannabis Inc (NASDAQ:ACB) is a cannabis production and distribution company operating in Canada and internationally, offering medical and consumer cannabis products, as well as plant propagation services. The companys diverse portfolio includes well-known medical cannabis brands such as MedReleaf, CanniMed, and Aurora.
From a business perspective, Aurora Cannabis has a significant presence in the Canadian cannabis market and is expanding its reach globally. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue can be analyzed. For instance, Auroras revenue growth rate can be compared to industry averages to gauge its competitive position.
In terms of valuation, Aurora Cannabis has a market capitalization of $235.38M USD, with a price-to-earnings (P/E) ratio of 18.86, indicating that the stock may be relatively expensive compared to its earnings. However, the forward P/E ratio is significantly higher at 95.24, suggesting that the market expects substantial earnings growth in the future. Return on Equity (RoE) is 0.28, which is a relatively low value, indicating that the company may not be generating sufficient profits from its equity.
To further analyze Aurora Cannabis stock performance, technical indicators such as moving averages and average true range (ATR) can be used. Although the current stock price is below its 20-day and 50-day simple moving averages (SMA20 and SMA50), it is still above its 52-week low, indicating some level of support. A more detailed analysis of the stocks price action and volatility can provide insights into potential trading opportunities.
ACB Stock Overview
| Market Cap in USD | 281m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-07-11 |
ACB Stock Ratings
| Growth Rating | -53.3% |
| Fundamental | 49.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -29.4% |
| Analyst Rating | 4.17 of 5 |
ACB Dividends
Currently no dividends paidACB Growth Ratios
| Growth Correlation 3m | 73.6% |
| Growth Correlation 12m | -7.4% |
| Growth Correlation 5y | -89.7% |
| CAGR 5y | -27.54% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.42 |
| Sharpe Ratio 12m | -0.85 |
| Alpha | 0.21 |
| Beta | 0.725 |
| Volatility | 62.95% |
| Current Volume | 923.2k |
| Average Volume 20d | 1029.7k |
| Stop Loss | 4.7 (-5.8%) |
| Signal | -0.85 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-20.1m TTM) > 0 and > 6% of Revenue (6% = 21.5m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 9.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 86.18% (prev 115.9%; Δ -29.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 17.8m > Net Income -20.1m (YES >=105%, WARN >=100%) |
| Net Debt (-33.3m) to EBITDA (36.2m) ratio: -0.92 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.3m) change vs 12m ago 8.76% (target <= -2.0% for YES) |
| Gross Margin 47.78% (prev 55.72%; Δ -7.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.69% (prev 33.19%; Δ 9.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.29 (EBITDA TTM 36.2m / Interest Expense TTM 8.46m) >= 6 (WARN >= 3) |
Altman Z'' -49.17
| (A) 0.37 = (Total Current Assets 465.3m - Total Current Liabilities 156.9m) / Total Assets 837.8m |
| (B) -7.62 = Retained Earnings (Balance) -6.38b / Total Assets 837.8m |
| warn (B) unusual magnitude: -7.62 — check mapping/units |
| (C) 0.02 = EBIT TTM 19.4m / Avg Total Assets 838.3m |
| (D) -25.62 = Book Value of Equity -6.38b / Total Liabilities 249.2m |
| Total Rating: -49.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.60
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -0.71% = -0.36 |
| 3. FCF Margin -0.80% = -0.30 |
| 4. Debt/Equity 0.28 = 2.46 |
| 5. Debt/Ebitda 4.21 = -2.50 |
| 6. ROIC - WACC (= -4.06)% = -5.08 |
| 7. RoE -3.60% = -0.60 |
| 8. Rev. Trend 88.50% = 6.64 |
| 9. EPS Trend 36.66% = 1.83 |
What is the price of ACB shares?
Over the past week, the price has changed by +0.40%, over one month by -2.54%, over three months by -15.14% and over the past year by -16.28%.
Is Aurora Cannabis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACB is around 3.65 USD . This means that ACB is currently overvalued and has a potential downside of -26.85%.
Is ACB a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.3 | 27.1% |
| Analysts Target Price | 6.3 | 27.1% |
| ValueRay Target Price | 4 | -19.8% |
Last update: 2025-09-18 04:30
ACB Fundamental Data Overview
CCE Cash And Equivalents = 140.2m CAD (Cash only, last quarter)
P/E Forward = 13.4048
P/S = 0.7859
P/B = 0.702
Beta = 3.44
Revenue TTM = 357.9m CAD
EBIT TTM = 19.4m CAD
EBITDA TTM = 36.2m CAD
Long Term Debt = 92.3m CAD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 59.8m CAD (from shortLongTermDebt, last quarter)
Debt = 152.1m CAD (Calculated: Short Term 59.8m + Long Term 92.3m)
Net Debt = -33.3m CAD (from netDebt column, last fiscal year)
Enterprise Value = 399.4m CAD (387.4m + Debt 152.1m - CCE 140.2m)
Interest Coverage Ratio = 2.29 (Ebit TTM 19.4m / Interest Expense TTM 8.46m)
FCF Yield = -0.71% (FCF TTM -2.85m / Enterprise Value 399.4m)
FCF Margin = -0.80% (FCF TTM -2.85m / Revenue TTM 357.9m)
Net Margin = -5.63% (Net Income TTM -20.1m / Revenue TTM 357.9m)
Gross Margin = 47.78% ((Revenue TTM 357.9m - Cost of Revenue TTM 186.9m) / Revenue TTM)
Tobins Q-Ratio = -0.06 (set to none) (Enterprise Value 399.4m / Book Value Of Equity -6.38b)
Interest Expense / Debt = 1.17% (Interest Expense 1.77m / Debt 152.1m)
Taxrate = 22.66% (4.62m / 20.4m)
NOPAT = 15.0m (EBIT 19.4m * (1 - 22.66%))
Current Ratio = 2.97 (Total Current Assets 465.3m / Total Current Liabilities 156.9m)
Debt / Equity = 0.28 (Debt 152.1m / last Quarter total Stockholder Equity 551.9m)
Debt / EBITDA = 4.21 (Net Debt -33.3m / EBITDA 36.2m)
Debt / FCF = -53.30 (Debt 152.1m / FCF TTM -2.85m)
Total Stockholder Equity = 558.8m (last 4 quarters mean)
RoA = -2.40% (Net Income -20.1m, Total Assets 837.8m )
RoE = -3.60% (Net Income TTM -20.1m / Total Stockholder Equity 558.8m)
RoCE = 2.97% (Ebit 19.4m / (Equity 558.8m + L.T.Debt 92.3m))
RoIC = 2.42% (NOPAT 15.0m / Invested Capital 618.0m)
WACC = 6.49% (E(387.4m)/V(539.6m) * Re(8.68%)) + (D(152.1m)/V(539.6m) * Rd(1.17%) * (1-Tc(0.23)))
Shares Correlation 3-Years: 90.08 | Cagr: 5.87%
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -2.85m)
EPS Correlation: 36.66 | EPS CAGR: -11.55% | SUE: -1.13 | # QB: 0
Revenue Correlation: 88.50 | Revenue CAGR: 28.43% | SUE: N/A | # QB: None
Additional Sources for ACB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle